Immunome Inc. IMNM
We are a biotechnology company committed to the development of first-in-class and best-in-class targeted oncology therapies. Our goal is to establish a broad portfolio of differentiated clinical assets to improve the lives of cancer patients. Key to that strategy is our deep expertise in the discovery, design, development, manufacturing, and ultimately commercialization of antibody-drug conjugates and other oncology therapeutics.
We are advancing a pipeline that includes three clinical assets and three preclinical assets. Varegacestat, formerly AL102, is an investigational, oral, once-daily gamma secretase inhibitor, or GSI. In December 2025, we announced positive topline results from the global pivotal Phase 3 RINGSIDE trial of varegacestat in patients with progressing desmoid tumors. We anticipate submitting a new drug application, or NDA, in the second quarter of 2026. IM-1021, a receptor tyrosine kinase-like orphan receptor 1, or ROR1, antibody-drug conjugate, is currently under evaluation in a Phase 1 trial. In November 2025, we reported observed objective responses at multiple dose levels in B-cell lymphoma patients treated with IM-1021, and we plan to share initial data in 2026. IM-3050, a fibroblast activation protein, or FAP, targeted radioligand therapy, or RLT, received IND clearance in April 2025, and we plan to initiate a Phase 1 trial in early 2026 after delivery of third-party diagnostic radiotracer supply. Our preclinical assets include three solid tumor ADCs with anticipated 2026 IND submissions: IM-1617, IM-1340, and IM-1335.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $6.9M | $9.0M | $14.0M | — | — | — | — | — |
| R&D | $177.3M | $129.5M | $23.1M | $23.3M | $14.1M | $7.5M | $8.8M | — |
| SG&A | $43.8M | $33.0M | $19.7M | $13.6M | $11.1M | $4.8M | $1.5M | — |
| Total operating expenses | $231.1M | $314.8M | $123.5M | $36.9M | $25.2M | $12.3M | $10.3M | — |
| Operating income | -$224.1M | -$305.8M | -$109.5M | -$36.9M | -$25.2M | -$12.3M | -$10.3M | — |
| Interest expense | $11.7M | $12.8M | $2.7M | $5.0K | $10.0K | $38.0K | $96.0K | — |
| Pre-tax income | -$212.4M | -$293.0M | -$106.8M | -$36.9M | -$24.7M | -$17.8M | -$10.4M | — |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | — |
| Net income | -$212.4M | -$293.0M | -$106.8M | -$36.9M | -$24.7M | -$17.8M | -$10.4M | — |
| EPS, basic | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | — | — |
| EPS, diluted | -2.43 | -5.00 | -5.38 | -3.09 | -2.14 | -5.26 | -9.55 | — |
| Shares, diluted (wtd. avg.) | 87.4M | 58.6M | 19.8M | 12.1M | 11.5M | 3.4M | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $653.5M | $143.4M | $98.8M | $20.4M | $49.3M | $39.9M | $2.6M | $1.7M |
| Short-term investments | $0 | $74.0M | $39.5M | — | — | — | — | — |
| Total current assets | $660.8M | $221.3M | $144.7M | $22.6M | $56.6M | $42.9M | $3.1M | — |
| Property, plant and equipment | $14.6M | $10.1M | $2.1M | $681.0K | $855.0K | $1.5M | $1.7M | — |
| Total assets | $683.2M | $240.2M | $148.5M | $24.0M | $57.9M | $44.5M | $5.1M | — |
| Accounts payable | $3.3M | $14.2M | $3.3M | $2.4M | $3.1M | $1.2M | $548.0K | — |
| Short-term debt | — | — | — | — | — | $366.0K | — | — |
| Total current liabilities | $45.0M | $54.3M | $21.8M | $7.3M | $9.7M | $3.0M | $1.7M | — |
| Long-term debt | — | — | — | — | — | $134.0K | — | — |
| Total liabilities | $48.8M | $59.1M | $28.7M | $7.4M | $9.7M | $3.2M | $1.8M | — |
| Retained earnings | -$728.2M | -$515.8M | -$222.8M | -$116.0M | -$79.1M | -$54.4M | -$36.6M | — |
| Total equity | $634.3M | $181.2M | $119.9M | $16.7M | $48.2M | $41.3M | -$35.6M | -$25.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$190.9M | -$110.8M | -$7.6M | -$28.7M | -$18.2M | -$12.1M | -$9.6M | — |
| Depreciation and amortisation | $2.5M | $1.6M | $457.0K | $422.0K | $755.0K | $755.0K | $615.0K | — |
| Stock-based compensation | $25.7M | $15.7M | $6.2M | $5.3M | $3.4M | $621.0K | $14.0K | — |
| Capital expenditure | $9.7M | $7.2M | $831.0K | $248.0K | $79.0K | $586.0K | $233.0K | — |
| Investing cash flow | $60.8M | -$85.1M | -$30.5M | -$248.0K | -$79.0K | -$586.0K | -$233.0K | — |
| Financing cash flow | $640.4M | $240.5M | $116.4M | $32.0K | $27.8M | $49.9M | $10.8M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001140361-26-016685.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | $14.0M | $9.0M | $6.9M |
| Gross profit | — | — | — | — | — | — | — | — |
| Net income | — | -$10.4M | -$17.8M | -$24.7M | -$36.9M | -$106.8M | -$293.0M | -$212.4M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Results announced Item 2.02
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event Item 8.01
- Results announced Item 2.02
- Results announced Item 2.02
- Shareholder vote Item 5.07
- Results announced Item 2.02
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |